Carl Dambkowski Sells 22,417 Shares of Oruka Therapeutics (NASDAQ:ORKA) Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) Director Carl Dambkowski sold 22,417 shares of the business’s stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $70.13, for a total transaction of $1,572,104.21. Following the completion of the transaction, the director owned 51,326 shares in the company, valued at $3,599,492.38. The trade was a 30.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Carl Dambkowski also recently made the following trade(s):

• On Friday, June 12th, Carl Dambkowski sold 12,583 shares of Oruka Therapeutics stock. The shares were sold at an average price of $70.11, for a total transaction of $882,194.13.
• On Thursday, May 21st, Carl Dambkowski sold 105,000 shares of Oruka Therapeutics stock. The shares were sold at an average price of $58.97, for a total transaction of $6,191,850.00.

Oruka Therapeutics Price Performance

NASDAQ:ORKA opened at $69.89 on Friday. The firm has a market capitalization of $4.22 billion, a price-to-earnings ratio of -36.03 and a beta of -0.26. The company’s 50-day moving average is $63.40 and its two-hundred day moving average is $43.94. Oruka Therapeutics, Inc. has a 1-year low of $10.77 and a 1-year high of $91.00.

Oruka Therapeutics (NASDAQ:ORKA) last posted its earnings results on Wednesday, May 13th. The company reported ($0.48) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.04. As a group, equities analysts anticipate that Oruka Therapeutics, Inc. will post -2.06 earnings per share for the current fiscal year.

Analyst Ratings Changes

ORKA has been the topic of a number of recent analyst reports. BTIG Research reissued a “buy” rating and issued a $151.00 price objective on shares of Oruka Therapeutics in a research report on Thursday, May 14th. HC Wainwright reissued a “buy” rating on shares of Oruka Therapeutics in a research report on Wednesday, June 3rd. Leerink Partners set a $120.00 price objective on shares of Oruka Therapeutics in a research report on Thursday, April 30th. Wall Street Zen downgraded shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. Finally, Piper Sandler reissued an “overweight” rating and issued a $180.00 price objective on shares of Oruka Therapeutics in a research report on Tuesday, June 2nd. Ten analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $131.30.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Royal Bank of Canada grew its position in shares of Oruka Therapeutics by 47.2% in the 4th quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock valued at $34,000 after buying an additional 365 shares during the last quarter. Los Angeles Capital Management LLC purchased a new position in shares of Oruka Therapeutics in the 4th quarter valued at $37,000. PNC Financial Services Group Inc. purchased a new position in shares of Oruka Therapeutics in the 3rd quarter valued at $39,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Oruka Therapeutics in the 4th quarter valued at $67,000. Finally, Russell Investments Group Ltd. purchased a new position in shares of Oruka Therapeutics in the 3rd quarter valued at $43,000. 56.44% of the stock is owned by hedge funds and other institutional investors.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.